

CURRENT REPORT 1/2025

January 29, 2025

Termination of STING program under Research Collaboration Option and Exclusive License Agreement with BioNTech SE

The Management Board of Ryvu Therapeutics S.A., with its registered office in Kraków, Poland ("Ryvu", the "Company"), informs that on January 29, 2025, BioNTech SE, with its registered office in Mainz, Germany ("BioNTech"), notified the Company that for reasons relating to change of BioNTech's portfolio strategy, the collaborator has decided to exercise its right to terminate the STING program covering Ryvu's STING agonist portfolio as standalone small molecules ("STING Program"; RVU312) along with two other of several previously undisclosed programs, which were implemented under the research collaboration and exclusive license agreement dated November 29, 2022 ("License Agreement"). The conclusion of the License Agreement was disclosed by the Company in its Current Report No. 26/2022, dated November 30, 2022.

As a result of the abovementioned termination, upon the expiration of 3-months' notice period, all licenses covering the terminated programs granted by the Company to BioNTech under the License Agreement will expire. Ryvu will regain full rights to the STING Program as standalone small molecules.

BioNTech and Ryvu will continue their multi-target research collaboration in the field of small molecule immunotherapy under the terms and conditions concluded in the License Agreement, including the funding by BioNTech of all discovery, research and development activities thereunder. The Company's financial projections consistently indicate that Ryvu's cash runway to Q1 2026 remains unchanged.

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: Article 17.1 of MAR

Representatives of the Issuer:

- Krzysztof Brzózka – Vice-President of the Management Board
- Kamil Sitarz – Member of the Management Board